Medicines labeled for the same conditions
Alternatives to efavirenz and lamivudine and tenofovir disoproxil
30 other medicines are given the same way (oral) and in the same FDA class as efavirenz and lamivudine and tenofovir disoproxil or labeled mainly for the same use (HIV); 14 are in its class, human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitors: etravirine, abacavir, nevirapine, zidovudine and 10 more; the others include 5 cytochrome p450 3a inhibitors, 4 protease inhibitors and 3 human immunodeficiency virus integrase strand transfer inhibitors (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $0.147 per nevirapine 200 mg tablet (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as efavirenz and lamivudine and tenofovir disoproxil?
The first 24 of the 30, the same class first. HIV lists all 47 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Efavirenz and lamivudine and tenofovir disoproxilhuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor | this medicine | 1 labeler | n/a | Yes | No current entry |
| Etravirinehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 5 labelers | $9.94 per tablet 200 mg tablet | No | A presentation being discontinued |
| Abacavirhuman immunodeficiency virus nucleoside analog reverse transcriptase inhibitor · same class | HIV | 12 labelers | $0.546 per tablet 300 mg tablet | Yes | No current entry |
| Nevirapinehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 6 labelers | $0.147 per tablet 200 mg tablet | Yes | No current entry |
| Zidovudinehuman immunodeficiency virus nucleoside analog reverse transcriptase inhibitor · same class | HIV | 3 labelers | $0.464 per tablet 300 mg tablet | Yes | No current entry |
| Bictegravir and emtricitabine and tenofovir alafenamidehepatitis b virus nucleoside analog reverse transcriptase inhibitor · same class | HIV | none listed | $136.73 per tablet 50-200-25 mg tablet | Yes | No current entry |
| Emtricitabinehuman immunodeficiency virus nucleoside analog reverse transcriptase inhibitor · same class | HIV | 2 labelers | $12.69 per capsule 200 mg capsule | Yes | A presentation being discontinued |
| Rilpivirinehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | 2 labelers | $48.04 per tablet 25 mg tablet | No | No current entry |
| Doravirinehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | none listed | $60.79 per tablet 100 mg tablet | No | No current entry |
| Emtricitabine and tenofovir alafenamidehepatitis b virus nucleoside analog reverse transcriptase inhibitor · same class | HIV | none listed | $74.94 per tablet 200-25 mg tablet | Yes | No current entry |
| Cobicistat, darunavir, emtricitabine and tenofovir alafenamidecytochrome p450 3a inhibitor · same class | HIV | none listed | $152.87 per tablet 800-150-200-10 mg tablet | Yes | No current entry |
| Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamidecytochrome p450 3a inhibitor · same class | HIV | none listed | $143.35 per tablet Genvoya tablet | Yes | No current entry |
| Dolutegravir and rilpivirinehuman immunodeficiency virus integrase strand transfer inhibitor · same class | HIV | none listed | $121.87 per tablet 50-25 mg tablet | No | No current entry |
| Doravirine and islatravirhuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | none listed | n/a | No | No current entry |
| Emtricitabine and rilpivirine and tenofovir alafenamidehuman immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor · same class | HIV | none listed | $130.49 per tablet Odefsey tablet | Yes | No current entry |
| Darunavirprotease inhibitor | HIV | 13 labelers | $1.16 per tablet 600 mg tablet | No | No current entry |
| Maravirocccr5 co-receptor antagonist | HIV | 8 labelers | $9.15 per tablet 150 mg tablet | Yes | A presentation being discontinued |
| Atazanavirprotease inhibitor | HIV | 4 labelers | $2.23 per capsule 300 mg capsule | No | No current entry |
| Ritonavircytochrome p450 3a inhibitor | HIV | 7 labelers | $0.607 per tablet 100 mg tablet | Yes | A presentation being discontinued |
| Lopinavir and ritonavircytochrome p450 3a inhibitor | HIV | 3 labelers | $4.46 per tablet 200-50 mg tablet | No | A presentation being discontinued |
| Raltegravirhuman immunodeficiency virus integrase strand transfer inhibitor | HIV | 1 labeler | $34.54 per tablet 400 mg tablet | No | No current entry |
| Dolutegravirhuman immunodeficiency virus integrase strand transfer inhibitor | HIV | none listed | $77.64 per tablet 50 mg tablet | No | No current entry |
| Cobicistat and darunavircytochrome p450 3a inhibitor | HIV | none listed | $79.99 per tablet 800 mg-150 mg tablet | No | No current entry |
| Fosamprenavirprotease inhibitor | HIV | 2 labelers | n/a | No | No current entry |
| Lenacapavirhuman immunodeficiency virus 1 capsid inhibitor | HIV | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Efavirenz and lamivudine and tenofovir disoproxil: the full record
- label, generics, price, shortages, recalls